Muscle and statins: from toxicity to the nocebo effect

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Statins are crucial for cardiovascular disease prevention but are associated with muscle symptoms.
• Statin-associated muscle symptoms (SAMS) are a common reason for treatment discontinuation.
• The incidence of SAMS is lower in controlled trials than in observational studies, suggesting non-pharmacological factors.

Purpose of the Study:

• To review the definition, prevalence, and clinical spectrum of SAMS.
• To discuss the diagnostic complexities of statin muscle intolerance.
• To highlight the role of the nocebo effect in SAMS and physician awareness.

Main Methods:

• This is a narrative review.
• Literature search on statin intolerance and SAMS.
• Focus on clinical presentation, diagnosis, and the nocebo effect.

Main Results:

• SAMS are the primary cause of statin intolerance.
• Discrepancies in SAMS incidence between trials and observational studies suggest other contributing factors.
• The nocebo effect is a significant consideration in managing statin intolerance.

Conclusions:

• Clinicians must consider non-pharmacological factors, including the nocebo effect, when evaluating SAMS.
• Premature discontinuation of statin therapy should be avoided.
• Improved patient communication and understanding of the nocebo effect are vital for managing statin intolerance.